Welcome to our dedicated page for Stoneridge SEC filings (Ticker: SRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story behind Stoneridge’s dual segments—how fast MirrorEye is ramping, which OEMs drive revenue, and when executives buy shares—means combing through pages of dense SEC language. Stock Titan surfaces answers instantly.
Our AI-powered summaries decode every document as soon as it hits EDGAR. Whether you need the Stoneridge annual report 10-K simplified for long-term strategy, a Stoneridge quarterly earnings report 10-Q filing to spot margin shifts, or a sudden Stoneridge 8-K material events explained alert, you’ll see the key numbers, risks, and segment commentary in plain English.
Stop refreshing multiple tabs. Real-time notifications flag Stoneridge Form 4 insider transactions real-time so you can track executive sentiment. Our platform also answers common searches automatically:
- “Stoneridge insider trading Form 4 transactions” – view buys and sells within minutes of filing.
- “Stoneridge proxy statement executive compensation” – compare pay packages against electronics R&D spend.
- “Understanding Stoneridge SEC documents with AI” – read concise, jargon-free briefs.
Every filing type is covered—10-K, 10-Q, 8-K, S-8, Schedule 13D/G. Interactive charts highlight how Electronics vs. Control Devices margins evolve, while sentence-level search pinpoints supplier-risk disclosures. Use our AI insights to:
- Run Stoneridge earnings report filing analysis without spreadsheet drudgery
- Monitor Stoneridge executive stock transactions Form 4 before material events
- Map R&D spending to future camera-based safety systems
With comprehensive coverage, expert commentary, and machine-readable data, Stock Titan turns complex Stoneridge filings into actionable intelligence—so you invest with clarity, not guesswork.
Stoneridge, Inc. (SRI) reported Q3 2025 results. Net sales were $210.3 million versus $213.8 million a year ago. The company posted an operating loss of $3.3 million and a net loss of $9.4 million, or $0.34 per share. For the first nine months, net sales were $656.1 million and the net loss was $25.9 million.
Cash provided by operating activities was $25.2 million year‑to‑date. Cash and cash equivalents were $54.0 million, and borrowings on the revolving credit facility were $170.2 million. On November 5, 2025, the company executed Amendment No. 2 to its credit agreement, reducing borrowing capacity to $225.0 million and extending covenant relief through November 2, 2026, while permitting a potential sale of the Control Devices business and adjusting interest coverage requirements.
Liquidity note: the credit facility matures on November 2, 2026 and will become current in Q4 2025; the company states its ability to continue as a going concern is contingent upon refinancing. Product warranty and recall reserves increased to $31.5 million. Business realignment charges were $2.1 million in Q3 and $6.6 million year‑to‑date.
Stoneridge, Inc. entered into Amendment No. 2 to its Fifth Amended and Restated Credit Agreement, providing covenant relief and restrictions through the Credit Facility’s termination on November 2, 2026.
Key changes include: borrowing capacity reduced from $275,000 to $225,000; the sale of the Control Devices business is permitted and, upon notice, will reduce the commitment by the lesser of $50,000 or the net cash proceeds; the minimum interest coverage ratio of 2.5 is extended through the quarter ending March 31, 2026 and increases to 3.5 for the quarter ended June 30, 2026 and thereafter, or to 3.5 as of the first full quarter after a Control Devices sale; and the maximum leverage ratio remains 4.5 for the quarter ended September 30, 2025 and 3.5 for the quarter ended December 31, 2025 and thereafter.
The company also furnished its third‑quarter 2025 results press release and related presentation, with a webcast by senior management on November 6, 2025.
Royce & Associates LP filed an amended Schedule 13G reporting beneficial ownership of 1,035,697 shares of Stoneridge, Inc. (SRI) common stock, representing 3.70% of the class. The filing indicates sole voting and sole dispositive power over the same number of shares and classifies the filer as an investment adviser (IA).
The position reflects ownership of 5 percent or less of the class, with the securities held in the ordinary course of business and not for the purpose of changing or influencing control. The date of event is 09/30/2025.
Dimensional Fund Advisors LP reported beneficial ownership of
The reporting address and organization details list Dimensional Fund Advisors LP as a Delaware limited partnership with a principal office in Austin, TX. The statement is signed by the Global Chief Compliance Officer on
22NW Fund and affiliated entities reported direct ownership of 1,943,508 common shares of Stoneridge Inc., equal to approximately 7.0% of the company's outstanding shares based on 27,846,292 shares outstanding as reported April 25, 2025. The shares are owned directly by 22NW Fund, and 22NW, 22NW Fund GP, 22NW GP, Inc. and Aron R. English may be deemed to beneficially own the same shares by virtue of their managerial and partner relationships, although each disclaims ownership of shares it does not directly hold. The statement was filed on Schedule 13G/A and includes a certification that the position was not acquired to affect control of the issuer.
Royce & Associates LP, an SEC-registered investment adviser, has filed a Schedule 13G disclosing beneficial ownership of 1,398,597 shares of Stoneridge, Inc. (SRI) common stock as of 30 Jun 2025. The stake equals 5.02 % of the outstanding shares, crossing the 5 % reporting threshold that triggers passive ownership disclosure under Rule 13d-1(b).
The firm reports sole voting and dispositive power over the entire position and no shared authority. Royce certifies the shares were acquired in the ordinary course of business, with no intent to influence or change control of the issuer. The filing is signed by Vice President Daniel A. O’Byrne on 22 Jul 2025.
- Reporting person: Royce & Associates LP, New York
- Form type: Schedule 13G (passive institutional investor)
- Date of event: 30 Jun 2025
- Ownership details: 1.40 MM shares; 5.02 % of class; sole voting/dispositive power
No financial results, transactions or governance changes are disclosed; the filing strictly reports Royce’s passive minority ownership.
Stoneridge CFO Matthew R. Horvath reported significant insider transactions on June 20, 2025. The transactions involved:
- Conversion of 29,103 Phantom Shares to common shares, followed by their immediate disposition
- Sale of these shares at $5.61 per share
- Reduction of direct holdings from 42,991 to 13,888 common shares
- Retention of 82,239 Share Units under the Company's Long-Term Incentive Plan, which vest on the third anniversary of their respective grant dates
The Phantom Shares were economically equivalent to common shares and were paid in cash. The transactions were executed according to standard reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. The filing was signed by Robert M. Loesch via power of attorney on June 24, 2025.
FAQ
What is the current stock price of Stoneridge (SRI)?
What is the market cap of Stoneridge (SRI)?
